Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Sociedad Quimica y Minera S.A. Common Stock (SQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Sociedad Quimica y Minera S.A. Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Sociedad Quimica y Minera S.A. Common Stock trades at $60.5 (market cap $17.61B). The key difference: Sociedad Quimica y Minera S.A. Common Stock is the larger of the two by market cap, and Sociedad Quimica y Minera S.A. Common Stock pays a 3.93% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Sociedad Quimica y Minera S.A. Common Stock for 6 Days on average.
| KYMR | SQM | |
|---|---|---|
Market Cap | $8.88B | $17.61B |
Volume | 1,028,790 | 996,244 |
Sector | Health | Basic Materials |
52-Week High | $127.31 | $95.31 |
52-Week Low | $55.80 | $42.39 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.27B | $18.47B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SQM trades at $62.83, up 0.58% today, but technical indicators signal a bearish trend with strong selling pressure. The company delivered mixed Q2 2026 earnings, beating EPS estimates with $2.31 vs. $2.03 expected, while Q1 and Q4 2025 missed expectations. Valuation metrics appear attractive with P/E of 12.93 and EV/EBITDA of 7.09, supported by strong profitability margins including 42.17% gross margin and 23.78% ROE.
Despite near-term technical weakness, SQM's fundamentals remain solid with projected revenue growth to $6.7B in 2026 and net profit margin expansion to 20.62%. The consensus price target of $92.50 suggests 47% upside potential, though lithium price volatility and recent earnings misses present execution risks. Analyst sentiment is mixed with 31% Buy ratings versus 19% Sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Sociedad Quimica y Minera S.A. Common Stock
SQM is a mining and chemical company operating in northern Chile. Its businesses include lithium, iodine, specialty plant nutrition, potassium, solar salts, and industrial chemicals.
Read more on SQM →
